Resource impact statement
No significant resource impact is anticipated
NICE has recommended fostamatinib as an option for treating refractory chronic immune thrombocytopenia in adults, only if:
- they have previously had a thrombopoietin receptor agonist (TPO-RA), or a TPO-RA is unsuitable
- the company provides fostamatinib according to the commercial arrangement.
This recommendation is not intended to affect treatment with fostamatinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because fostamatinib is a further treatment option for patients who have not had a suitable response to prior therapy including a TPO-RA, or where use of a TPO-RA is not appropriate, and the overall cost of treatment will be similar to the current treatment options.
The company has a commercial arrangement (simple discount patient access scheme). This makes fostamatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount.
This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.
This page was last updated: